Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · TTNP · as of Jun 8, 2026
Activity summary
Buy transactions
2
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
1.00
Buy/Sell (by trades)
Overall sentiment
Titan Pharmaceuticals, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
TTNP insider buying and selling by quarter
TTNP insider selling · TTNP insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · TTNP ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
TTNP executive sell shares · TTNP board member insider trading · TTNP insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 1, 2025 | Ben-Tzvi Avraham Director | Other | 3,313 | — | Form 4 |
| Mar 18, 2024 | Choong Choon Hau 10 percent owner | Other | 54,132 | — | Form 4 |
| Oct 25, 2023 | NATAN DAVID Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | McMurdo Matthew Charles Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Greenberg Eric Howard Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Beebe Katherine President and COO · Director | Award | 16,250 | — | Form 4 |
| Oct 25, 2023 | Ben-Tzvi Avraham Director | Award | 16,250 | — | Form 4 |
| Jul 26, 2023 | Greenberg Eric Howard Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | Lazar David E. CEO · Director | Award | 100,000 | — | Form 4 |
| Jul 26, 2023 | Ben-Tzvi Avraham Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | Beebe Katherine President and COO · Director | Award | 50,000 | — | Form 4 |
| Jul 26, 2023 | McMurdo Matthew Charles Director | Award | 50,000 | — | Form 4 |
| Jan 28, 2022 | MCNAB JAMES R Director | Other | 51,021 | $2.55B⚡ | Form 4 |
| Oct 19, 2018 | Recli Federico Seghi Director | Purchase | 200,000 | $82K | Form 4 |
| Sep 24, 2018 | Recli Federico Seghi Director | Purchase | 500,000 | $114K | Form 4 |
| Sep 21, 2018 | MACFARLANE M DAVID Director | Purchase | 80,000 | $20K | Form 4 |
| Sep 21, 2018 | BHONSLE SUNIL See Remarks · Director | Purchase | 300,000 | $75K | Form 4 |
| Sep 21, 2018 | MCNAB JAMES R Director | Purchase | 200,000 | $50K | Form 4 |
| Sep 21, 2018 | Rubin Marc Executive Chairman · Director | Purchase | 400,000 | $100K | Form 4 |
| Sep 21, 2018 | Akers Joseph A Director | Purchase | 200,000 | $50K | Form 4 |
| Jul 19, 2016 | Akers Joseph A Director | Purchase | 5,000 | $23K | Form 4 |
| Jul 18, 2016 | Akers Joseph A Director | Purchase | 8,000 | $40K | Form 4 |
| Jul 18, 2016 | BHONSLE SUNIL President and CEO · Director | Purchase | 10,000 | $50K | Form 4 |
Beebe Katherine
President and COO · Director
Date
Oct 25
Shares
16,250
Price
—
Value
—
Beebe Katherine
President and COO · Director
Date
Jul 26
Shares
50,000
Price
—
Value
—
Recli Federico Seghi
Director
Date
Oct 19
Shares
200,000
Price
$0.41
Value
$82K
Recli Federico Seghi
Director
Date
Sep 24
Shares
500,000
Price
$0.23
Value
$114K
BHONSLE SUNIL
See Remarks · Director
Date
Sep 21
Shares
300,000
Price
$0.25
Value
$75K
Rubin Marc
Executive Chairman · Director
Date
Sep 21
Shares
400,000
Price
$0.25
Value
$100K
BHONSLE SUNIL
President and CEO · Director
Date
Jul 18
Shares
10,000
Price
$4.96
Value
$50K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About TTNP insider trading
TTNP insider trades
Titan Pharmaceuticals, Inc. (TTNP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Ben-Tzvi Avraham (Director). Over the past 12 months, 1 insiders have filed transactions with the SEC. TTNP insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Titan Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
TTNP insider trading · 5 questionsThe insiders of Titan Pharmaceuticals, Inc. (TTNP) include executives and directors such as Ben-Tzvi Avraham (Director), among others. Over the past 12 months, 1 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026